2023 年第 7 期 第 18 卷

前蛋白转化酶枯草溶菌素9抑制剂对动脉粥样硬化性心血管疾病患者临床疗效的研究进展

Research progress on clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitor in patients with atherosclerotic cardiovascular disease

作者：刘霖泽林文华

英文作者：Liu Linze Lin Wenhua

单位：泰达国际心血管病医院心内一科，天津300070

英文单位：First Department of Cardiology TEDA International Cardiovascular Hospital Tianjin 300070 China

关键词：动脉粥样硬化性心血管疾病；低密度脂蛋白胆固醇；前蛋白转化酶枯草溶菌素9抑制剂；研究进展

英文关键词：Atheroseleroticcardiovasculardisease；Low-densitylipoproteincholesterol；Proproteinconvertasesubtilisin/kexintype9inhibitors；Researchprogress

• 摘要：

• 高脂血症是动脉粥样硬化性心血管疾病（ASCVD）的重要危险因素，长期的高脂血症会导致动脉粥样硬化及其斑块持续进展。积极控制血脂水平，尤其是控制低密度脂蛋白胆固醇水平是治疗中重要的一环。前蛋白转化酶枯草溶菌素9抑制剂（PCSK9i）是一种新型降脂药，不仅可以明显降低ASCVD患者的低密度脂蛋白胆固醇水平，改善ASCVD患者临床预后，还可以促使粥样斑块发生逆转。本文综述了近年来关于PCSK9i对ASCVD患者临床疗效的研究进展，以期为临床提供一定参考。

• Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD), long-term hyperlipidemia can lead to continuous progress of atherosclerosis and its plaques. Active control of blood lipid levels, particularly low-density lipoprotein cholesterol (LDL-C) levels, is an important part of treatment. Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) is a new type of lipid-lowering drug, which can not only significantly reduce LDL-C levels in patients with ASCVD, improve the clinical prognosis of patients with ASCVD, but also promote the reversal of atherosclerotic plaques. This paper reviews the research progress on the clinical efficacy of PCSK9i in patients with ASCVD in recent years, in order to provide some references for clinical diagnosis and treatment.